$NMRA

Neumora Therapeutics (Nasdaq: NMRA) reported Q2 2026 results and a pipeline update. It said NMRA-215 IND submission is planned for Q4 2026 with Phase 1 initiation by year end. NMRA-511 AD agitation data are expected in Q4 2026, and NMRA-898 schizophrenia Phase 1 data in 2H 2026. Cash was $116.8M, funding operations into Q3 2027; Q2 net loss was $43.1M.

Neumora Therapeutics, Inc. (NMRA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 nmra-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update Favorable pre-clinical data reported for NMRA-215 with plan to submit IND in fourth quarter of 2026 and initiate Phase 1 study by

Biotech news roundup: Spero (SPRO) and GSK won FDA approval for Utebzi (tebipenem pivoxil) for complicated UTIs; AbbVie (ABBV) expanded FDA approval of SKINVIVE by JUVÉDERM to neck lines; Cuprina (CUPR) received 510(k) clearance for MEDIFLY maggots. Neumora (NMRA) halted KOASTAL Phase 3 and plans 35% layoffs; enGene (ENGN) cuts ~50%. Biogen (BIIB) agreed to buy RayThera for up to $1B.

Levi & Korsinsky said it has opened an investigation into Neumora Therapeutics’ officers and directors after the company disclosed that navacaprant failed both Phase 3 KOASTAL-2 and KOASTAL-3 trials in major depressive disorder and announced an immediate ~35% workforce reduction. The article notes the stock fell nearly 50% and cites prior company comments during earnings and in January 2026.

Neumora Therapeutics, Inc. (NMRA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. 8-K false 0001885522 0001885522 2026-06-10 2026-06-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10,

The article indicates that Neumora exceeded fourth-quarter earnings forecasts, driven by progress in its pipeline. Despite the positive financial performance and pipeline advancements, the company's shares experienced a decline.

Neumora Therapeutics has been downgraded from 'Strong Buy' to 'Hold' following the failure of its KOASTAL-1 study for navacaprant in Major Depressive Disorder (MDD). Although enrollment for KOASTAL-2 and KOASTAL-3 studies in MDD has increased with topline data expected in Q2 2026, success is uncertain. The company's NMRA-511 showed a promising signal for Alzheimer's Disease agitation in a Phase 1b study, particularly in patients with elevated anxiety, but a Phase 2 study is not anticipated until Q1 2027, delaying near-term value realization.

Top executives at Neumora Therapeutics (NMRA) recently engaged in coordinated stock sales, with CEO Paul Berns, COO Aurora Daljit Singh, and President Joshua Pinto cashing out shares totaling over $77,000. These transactions follow positive analyst attention due to favorable Phase Ib data for NMRA-511, a drug for Alzheimer’s disease agitation, which sparked a more optimistic valuation outlook for the company. Despite the insider selling, TipRanks’ AI Analyst, Spark, rates NMRA as "Neutral" due to weak financial performance tempered by constructive technical positioning and a promising pipeline.

WATERTOWN, Mass., Nov. 03, 2025 ( GLOBE NEWSWIRE ) -- Neumora Therapeutics, Inc. ( NASDAQ:NMRA ) , a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, ...

NMRA-898 is structurally distinct from NMRA-861 and is the second M4 PAM in Neumora's M4 franchise; both programs have potential best-in-class pharmacology No convulsions observed in pre-clinical studies conducted in multiple species, including rabbits